ERYTECH PHARMA SA

ERYTECH Completes Patient Enrollment in Phase 2 Trial of eryaspase (GRASPA(R)) for Pancreatic Cancer

ERYTECH Provides Business Update and Reports Financial Results for Full Year 2015

ERYTECH reports financial highlights for Q4 2015

ERYTECH provides business update and financial results for the first half of 2015

ERYTECH provides business update and financial results for the full year 2014

ERYTECH announces ADR Level 1 listing in the US

ERYTECH reports additional positive Phase III results from clinical study with ERY-ASP/GRASPA(R) in Acute Lymphoblastic Leukemia

ERYTECH successfully raises EUR30 million for expanding its therapeutic indications in oncology and accelerating its clinical developments

ERYTECH PHARMA SA: ERYTECH announces granting of new patent in the United States

ERYTECH announces granting of new patent in the United States

ERYTECH reports positive top-line Phase III results from clinical study with GRASPA(R) in Acute Lymphoblastic Leukemia

ERYTECH PHARMA SA: Business Update and Financial Results for the First Half of 2014